NO331082B1 - Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft - Google Patents

Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft

Info

Publication number
NO331082B1
NO331082B1 NO20031860A NO20031860A NO331082B1 NO 331082 B1 NO331082 B1 NO 331082B1 NO 20031860 A NO20031860 A NO 20031860A NO 20031860 A NO20031860 A NO 20031860A NO 331082 B1 NO331082 B1 NO 331082B1
Authority
NO
Norway
Prior art keywords
formulation
reconstituted solution
kahalalide
medicament
cancer
Prior art date
Application number
NO20031860A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031860L (no
NO20031860D0 (no
Inventor
Glynn Thomas Faircloth
Graham Keith Ruffles
Bastian Nuyen
Steve Weitman
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of NO20031860D0 publication Critical patent/NO20031860D0/no
Publication of NO20031860L publication Critical patent/NO20031860L/no
Publication of NO331082B1 publication Critical patent/NO331082B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Liquid Crystal Substances (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
NO20031860A 2000-10-31 2003-04-25 Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft NO331082B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24447100P 2000-10-31 2000-10-31
US24622900P 2000-11-06 2000-11-06
US34844901P 2001-10-19 2001-10-19
PCT/GB2001/004821 WO2002036145A2 (fr) 2000-10-31 2001-10-31 Kahalalide f

Publications (3)

Publication Number Publication Date
NO20031860D0 NO20031860D0 (no) 2003-04-25
NO20031860L NO20031860L (no) 2003-06-30
NO331082B1 true NO331082B1 (no) 2011-10-03

Family

ID=27399760

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031860A NO331082B1 (no) 2000-10-31 2003-04-25 Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft

Country Status (22)

Country Link
US (1) US7473681B2 (fr)
EP (1) EP1330258B1 (fr)
JP (2) JP2004512370A (fr)
KR (1) KR100834138B1 (fr)
CN (1) CN1568192A (fr)
AT (1) ATE314084T1 (fr)
AU (2) AU2002210749B2 (fr)
BR (1) BR0114912A (fr)
CA (1) CA2425627A1 (fr)
CY (1) CY1105009T1 (fr)
CZ (1) CZ20031211A3 (fr)
DE (1) DE60116359T2 (fr)
DK (1) DK1330258T3 (fr)
ES (1) ES2256305T3 (fr)
HK (1) HK1054192B (fr)
HU (1) HUP0600031A3 (fr)
IL (2) IL155297A0 (fr)
MX (1) MXPA03003704A (fr)
NO (1) NO331082B1 (fr)
NZ (1) NZ525243A (fr)
SK (1) SK286421B6 (fr)
WO (1) WO2002036145A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
WO2003033012A1 (fr) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Composes a base de kahalalide utilisables en therapie anticancereuse
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
DE60335292D1 (de) * 2002-10-18 2011-01-20 Pharma Mar Sau 4-methylhexanoic kahalalide f verbindung
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
CN100591691C (zh) * 2002-10-18 2010-02-24 马尔药品公司 新型抗肿瘤化合物
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
DE10329847A1 (de) * 2003-07-02 2005-01-20 Toximed Gmbh Pharmazeutischer Wirkstoff gegen Prostatakarzinome
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
PL1827500T3 (pl) * 2004-10-26 2009-09-30 Pharma Mar Sa Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
ES2290844T3 (es) * 2004-10-29 2008-02-16 Pharma Mar S.A., Sociedad Unipersonal Composiciones que comprenden ecteinascidinas y un disacarido.
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US20100226919A1 (en) * 2007-10-19 2010-09-09 Pharma Mar, S.A. Antitumoral Treatments
US20100323021A1 (en) * 2008-01-30 2010-12-23 Pharma Mar, S.A. Antitumoral treatments
US20110015135A1 (en) * 2008-03-07 2011-01-20 Pharma Mar S.A. Antitumoral Treatments
WO2009135939A2 (fr) * 2008-05-09 2009-11-12 Pharma Mar, S.A. Depsipeptide pour une utilisation dans la thérapie du cancer
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
JP2799483B2 (ja) 1988-03-09 1998-09-17 大塚製薬株式会社 インターロイキン−１β組成物の安定化方法
GB8819607D0 (en) 1988-08-17 1988-09-21 Wellcome Found Novel combination
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
JP2971680B2 (ja) 1991-10-02 1999-11-08 山之内製薬株式会社 組織プラスミノーゲン活性化因子含有組成物
JPH0597703A (ja) 1991-10-04 1993-04-20 Yamanouchi Pharmaceut Co Ltd 改変型組織プラスミノーゲン活性化因子含有組成物
US5550124A (en) 1991-12-10 1996-08-27 University Of Southern California Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
JPH1014581A (ja) 1996-07-08 1998-01-20 Morinaga Milk Ind Co Ltd ウサギ型マクロファージ・コロニー刺激因子及びこれをコードするｄｎａ断片
US6139838A (en) 1996-09-06 2000-10-31 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Tissue plasminogen activator medicinal composition
JP4025394B2 (ja) * 1996-09-06 2007-12-19 財団法人化学及血清療法研究所 組織プラスミノーゲン活性化因子医薬組成物
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
AP2001002113A0 (en) 1998-09-23 2001-06-30 Marcus Keep Neuroimmunophilins for selective neuronal radioprotection.
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy

Also Published As

Publication number Publication date
CN1568192A (zh) 2005-01-19
JP2004512370A (ja) 2004-04-22
US7473681B2 (en) 2009-01-06
IL155297A (en) 2010-05-31
HK1054192B (zh) 2006-09-08
SK5022003A3 (en) 2003-12-02
ATE314084T1 (de) 2006-01-15
PL360848A1 (en) 2004-09-20
IL155297A0 (en) 2003-11-23
JP2010047601A (ja) 2010-03-04
WO2002036145A8 (fr) 2003-10-23
DE60116359T2 (de) 2006-09-28
WO2002036145A3 (fr) 2002-10-17
HUP0600031A3 (en) 2012-02-28
AU2002210749B2 (en) 2006-12-21
DE60116359D1 (de) 2006-02-02
MXPA03003704A (es) 2004-05-04
NO20031860L (no) 2003-06-30
EP1330258A2 (fr) 2003-07-30
WO2002036145A2 (fr) 2002-05-10
SK286421B6 (sk) 2008-09-05
KR20030044005A (ko) 2003-06-02
CA2425627A1 (fr) 2002-05-10
HK1054192A1 (en) 2003-11-21
CZ20031211A3 (cs) 2003-09-17
DK1330258T3 (da) 2006-05-22
NZ525243A (en) 2005-01-28
ES2256305T3 (es) 2006-07-16
HUP0600031A2 (en) 2006-05-29
EP1330258B1 (fr) 2005-12-28
BR0114912A (pt) 2003-10-14
US20040067895A1 (en) 2004-04-08
AU1074902A (en) 2002-05-15
NO20031860D0 (no) 2003-04-25
CY1105009T1 (el) 2010-03-03
KR100834138B1 (ko) 2008-06-02

Similar Documents

Publication Publication Date Title
NO331082B1 (no) Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft
HRP20041152B1 (en) Pharmaceutical formulations
SE0102315D0 (sv) Compounds
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
SE0100901D0 (sv) New composition
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
DK1172114T3 (da) Stabile koncentrerede insulinpræparater til pulmonær indgivelse
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
MY118151A (en) Pharmaceutical formulations containing voriconazole.
EA200601524A1 (ru) Альфа-излучающие частицы гидроксиапатита
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
ATE231872T1 (de) Thiazolopyrimidinderivate
DK0994710T4 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzylhydrylpiperazin og en cyclodextrin
SE0300831D0 (sv) New formulations and use therof
AR030829A1 (es) Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
HK1068606A1 (en) Novel aminobenzoephenones
NO20023935L (no) Ny, ikke-antigen, mukosal adjuvansformulering som modulerer effektene av substanser inkludert vaksineantigener, i kontakt medmukosale kroppsoverflater
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
DE60112756D1 (de) Racecadotril enthaltende trockene pulverformulierung
ITMI20022777A1 (it) Formulazioni farmaceutiche per ormoni tiroidei e procedimenti per il loro ottenimento.
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
SE0200657D0 (sv) Novel Formulation
ITMI20031714A1 (it) Formazioni ad azione antitumorale.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees